Effect Evaluation of hepatoprotective drug shuifeijibin on patients with antituberculosis treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002076

Enrollment

Unknown

Registered

2012-03-06

Start date

2012-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

A:Standard antituberculosis treatment+hepatoprotective drug shuifeijibin

B:Standard antituberculosis treatment+Vitamin C

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Be diagnosed tuberculosis by the diagnostic criteria; (2) Aged 18-60 years old, no limit on gender; (3) Normal liver funtion; (4) Good compliance and willing to sign informed consent.

Exclusion criteria

Exclusion criteria: (1) be infected with HIV; (2) a history of liver disease; (3) alcoholism; (4) taking other liver-induced drugs combined with antituberculosis drug during therapy; (5) Hepatitis B surface antigen or Hepatitis C antibody positive; (6) refuse to participate.

Design outcomes

Primary

Measure	Time frame
Incidence of hepatotoxicy;blood routine;liver function test;	—

Countries

China

Contacts

Public ContactJianming Wang

merry21st@yahoo.com.cn+86 15996496360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026